Impact of Aurora Kinase A Polymorphism and Epithelial Growth Factor Receptor Mutations on the Clinicopathological Characteristics of Lung Adenocarcinoma

Po-Jen Yang, Ming-Ju Hsieh, Chun-I Lee, Chi-Hua Yen, Hsiang-Ling Wang, Whei-Ling Chiang, Tu-Chen Liu, Thomas Chang-Yao Tsao, Chia-Yi Lee and Shun-Fa Yang
Additional contact information
Po-Jen Yang: School of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
Ming-Ju Hsieh: Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
Chun-I Lee: Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
Chi-Hua Yen: School of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
Hsiang-Ling Wang: Department of Beauty Science, National Taichung University of Science and Technology, Taichung 404, Taiwan
Whei-Ling Chiang: School of Medical Laboratory and Biotechnology, Chung Shan Medical University, Taichung 402, Taiwan
Tu-Chen Liu: Department of Chest Medicine, Cheng-Ching General Hospital, Taichung 407, Taiwan
Thomas Chang-Yao Tsao: School of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
Chia-Yi Lee: Department of Ophthalmology, Show Chwan Memorial Hospital, Changhua 500, Taiwan
Shun-Fa Yang: Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan

IJERPH, 2020, vol. 17, issue 19, 1-11

Abstract: Lung adenocarcinoma (LADC) is the most common subtype of lung cancer worldwide and the epidermal growth factor receptor (EGFR) has a great influence on its clinical course, mainly due to the influence of different phenotypes. The Aurora kinase A (AURKA) would influence the progression of several solid malignancies. However, whether the interaction between EGFR phenotypes and AURKA would influence the clinical characteristics of LADC remains unknown. Herein, this study aimed to explore the effects of single-nucleotide polymorphisms (SNPs) of AURKA and EGFR phenotypes on the clinicopathological characteristics of LADC. Four loci of AURKA SNPs ( rs1047972, rs2273535, rs6024836 , and rs2064863 ) were genotyped using TaqMan allelic discrimination in 105 wild-type EGFR individuals and 167 LADC patients with EGFR mutations. After the statistical analysis, patients with LADC who had CT heterozygotes of AURKA rs1047972 had a lower risk of EGFR mutations than patients with wild-type homozygotes. Moreover, female and nonsmoking patients who carried the CT genotype of AURKA rs1047972 had a lower risk of EGFR mutation ( p = 0.008 and p = 0.004, respectively). Moreover, in patients with EGFR mutations, AURKA SNP rs6024836 G allele (AG + GG) carriers had a lower risk of developing advanced-stage LADC (stage III or IV; odds ratio = 0.423, 95% confidence interval: 0.203–0.879, p = 0.019) than patients with AA homozygotes. Our results suggested that AURKA rs1047972 variants are significantly associated with EGFR mutations among patients with LADC, particularly in female and nonsmoking patients. AURKA variants may contribute to the pathological development of LADC.

Keywords: AURKA; epidermal growth factor receptor; single-nucleotide polymorphism; lung adenocarcinoma (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2020
References: View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.mdpi.com/1660-4601/17/19/7350/pdf (application/pdf)
https://www.mdpi.com/1660-4601/17/19/7350/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:17:y:2020:i:19:p:7350-:d:425064

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().